Natera revenue surges 39% to $697M on oncology momentum; loss widens on R&D ramp

Filed May 8, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 9, 2025 · ~1 min read

Key Changes

• high

  Revenue grew 38.8% to $696.6M in Q1 2026, driven by 54.4% surge in oncology test volumes (258,900 tests) as Signatera, Latitude, and Altera gain commercial traction.

  MD&A: Revenue Growth verify on EDGAR →
• high

  Net loss widened 27% to $85.1M from $66.9M as R&D spending jumped 63% ($81.6M increase) on expanded clinical trials, headcount growth, and infrastructure investments.

  MD&A: Operating Expenses verify on EDGAR →
• high

  Foresight Diagnostics acquisition closed between periods, adding $5.7M in intangible amortization and expanding oncology portfolio with tissue-free MRD capabilities.

  MD&A: Acquisitions verify on EDGAR →